Special Issue

Bioinformatic Analysis of NGS Data

Message from the Guest Editors

With the fast advances in next generation sequencing (NGS) technologies, NGS and its associated bioinformatic analysis techniques have revolutionised omics disciplines over the past 15 years. There are two major paradigms in NGS technologies: short-read sequencing and long-read sequencing. Short-read sequencing, such as Illumina, offers cost-effective and high-accuracy data that have wide applications for research in genomics, transcriptomics, and epigenomics. By contrast, long-read sequencing, such as Oxford Nanopore and PacBio, is well-tailored for applications like de novo assembly and/or full-length sequencing for RNA, circular RNAs, extrachromosomal circular DNA elements, etc.

This Special Issue in Genes will focus on the bioinformatic analysis of NGS data and the applications of NGS in various research areas. We welcome original articles, new methods and reviews covering any aspect of NGS data analysis.

We look forward to receiving your contributions.

Guest Editors

Dr. Qiongyi Zhao

Queensland Brain Institute, The University of Queensland, Brisbane 4072, Australia

Dr. Pei Hao

Institute Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China

Deadline for manuscript submissions

closed (20 June 2022)

GCAT
TACG
GCAT

Genes

an Open Access Journal by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed

mdpi.com/si/102570

Genes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
genes@mdpi.com

mdpi.com/journal/genes

MDPI

GCAT
TACG
GCAT

Genes

an Open Access Journal by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed

mdpi.com/journal/genes

MDPI

About the Journal

Message from the Editor-in-Chief

Genes is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan
Experimental Cancer Therapeutics, The University of Alabama at Birmingham, 1825 University Blvd., SHEL 814, Birmingham, AL 35294-2182, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))